Last reviewed · How we verify
EVARREST® Fibrin Sealant Patch
At a glance
| Generic name | EVARREST® Fibrin Sealant Patch |
|---|---|
| Also known as | EVARREST |
| Sponsor | Ethicon, Inc. |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparing Clinical Outcomes of the One-step Cartilage Transplantation in Cartilage Defects of the Knee With Conservative Treatment (PHASE3)
- Clinical Study of Chondro-Gide® for Large Chondral Lesions in the Knee (NA)
- The EVARREST® Pediatric Mild or Moderate Liver and Soft Tissue Bleeding Study (PHASE3)
- A Study Evaluating the Safety and Preliminary Efficacy of sFilm-FS in Controlling Parenchymal Bleeding During Elective Hepatic Surgery (PHASE1, PHASE2)
- Cartilage Repair Using a Hyaluronic Acid-Based Scaffold With Bone Marrow Aspirate Compared With Microfracture for Focal Articular Cartilage Damage of the Hip (NA)
- AMIC vs. MFx in the Ankle (NA)
- Use of Fibrin Sealant Patch for Vein Anastomosis During Deceased Donor Liver Transplantation- Randomized Clinical Trial (PHASE4)
- The EVARREST® Paediatric Mild/Moderate Liver and Soft Tissue Bleeding Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EVARREST® Fibrin Sealant Patch CI brief — competitive landscape report
- EVARREST® Fibrin Sealant Patch updates RSS · CI watch RSS
- Ethicon, Inc. portfolio CI